Tian et al postulated that during DCA treatment individuals homozygous for −1002A will re‐express the GSTZ1 protein at a lower rate or amount, resulting in susceptibility to accumulation of DCA and increased peripheral neuropathy. This evidence concerns the gene GSTZ1 and peripheral neuropathy.